These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 7636241

  • 1. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation.
    Zhu Z, Carter P.
    J Immunol; 1995 Aug 15; 155(4):1903-10. PubMed ID: 7636241
    [Abstract] [Full Text] [Related]

  • 2. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.
    Int J Cancer Suppl; 1992 Aug 15; 7():45-50. PubMed ID: 1428403
    [Abstract] [Full Text] [Related]

  • 3. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
    Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA.
    J Immunol; 1992 May 01; 148(9):2756-63. PubMed ID: 1533410
    [Abstract] [Full Text] [Related]

  • 4. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
    Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H.
    Eur J Immunol; 1993 Feb 01; 23(2):403-11. PubMed ID: 8436176
    [Abstract] [Full Text] [Related]

  • 5. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS, Anasetti C, Tso JY.
    J Immunol; 1997 Oct 01; 159(7):3613-21. PubMed ID: 9317161
    [Abstract] [Full Text] [Related]

  • 6. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
    Zhu Z, Lewis GD, Carter P.
    Int J Cancer; 1995 Jul 28; 62(3):319-24. PubMed ID: 7628874
    [Abstract] [Full Text] [Related]

  • 7. Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3.
    van Lier RA, Boot JH, Verhoeven AJ, de Groot ER, Brouwer M, Aarden LA.
    J Immunol; 1987 Nov 01; 139(9):2873-9. PubMed ID: 3117878
    [Abstract] [Full Text] [Related]

  • 8. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H, Nie Y, Huse WD, Watkins JD.
    J Mol Biol; 1999 Nov 19; 294(1):151-62. PubMed ID: 10556035
    [Abstract] [Full Text] [Related]

  • 9. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.
    Sato K, Ohtomo T, Hirata Y, Saito H, Matsuura T, Akimoto T, Akamatsu K, Koishihara Y, Ohsugi Y, Tsuchiya M.
    Hum Antibodies Hybridomas; 1996 Nov 19; 7(4):175-83. PubMed ID: 9140729
    [Abstract] [Full Text] [Related]

  • 10. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
    Bortoletto N, Scotet E, Myamoto Y, D'Oro U, Lanzavecchia A.
    Eur J Immunol; 2002 Nov 19; 32(11):3102-7. PubMed ID: 12385030
    [Abstract] [Full Text] [Related]

  • 11. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M, Weth R, Wels WS.
    J Mol Biol; 2005 Mar 11; 346(5):1299-311. PubMed ID: 15713482
    [Abstract] [Full Text] [Related]

  • 12. Anti-CD3:anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro.
    MacLean JA, Su Z, Guo Y, Sy MS, Colvin RB, Wong JT.
    J Immunol; 1993 Feb 15; 150(4):1619-28. PubMed ID: 8432997
    [Abstract] [Full Text] [Related]

  • 13. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
    Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, Scopinaro F, Dierckx R, Signore A.
    J Nucl Med; 2009 Oct 15; 50(10):1683-91. PubMed ID: 19759100
    [Abstract] [Full Text] [Related]

  • 14. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
    Zollner TM, Zhu HG, Anderer FA.
    Anticancer Res; 1993 Oct 15; 13(4):923-30. PubMed ID: 8352560
    [Abstract] [Full Text] [Related]

  • 15. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
    Silva HM, Vieira PM, Costa PL, Pimentel BM, Moro AM, Kalil J, Maranhão AQ, Coelho V, Brigido MM.
    Immunol Lett; 2009 Aug 15; 125(2):129-36. PubMed ID: 19573559
    [Abstract] [Full Text] [Related]

  • 16. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys.
    Co MS, Baker J, Bednarik K, Janzek E, Neruda W, Mayer P, Plot R, Stumper B, Vasquez M, Queen C, Loibner H.
    Cancer Res; 1996 Mar 01; 56(5):1118-25. PubMed ID: 8640770
    [Abstract] [Full Text] [Related]

  • 17. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, Junghans RP.
    Clin Cancer Res; 1999 Dec 01; 5(12):3928-41. PubMed ID: 10632322
    [Abstract] [Full Text] [Related]

  • 18. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
    Liao KW, Chen BM, Liu TB, Tzou SC, Lin YM, Lin KF, Su CI, Roffler SR.
    Cancer Gene Ther; 2003 Oct 01; 10(10):779-90. PubMed ID: 14502231
    [Abstract] [Full Text] [Related]

  • 19. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A, Mathas S, Jensen M, Tillmann T, Menges M, Diehl V, Kruis W, Pohl C.
    Anticancer Res; 1997 Oct 01; 17(3C):2025-32. PubMed ID: 9216660
    [Abstract] [Full Text] [Related]

  • 20. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y, Suzuki Y, Katakura R, Miyagi T, Yamaguchi T, Yoshimoto T, Ebina T.
    Clin Cancer Res; 1997 Apr 01; 3(4):633-43. PubMed ID: 9815731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.